In the described pediatric SMA population with small numbers of SMN2-gene copies and onasemnogene abeparvovec treatment, we believe that the majority of children will develop progressive spinal deformity in early childhood and will most likely need early GFSI treatment for deformity control. This evidence concerns the gene SMN2 and proximal spinal muscular atrophy.